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Immunoevasionis the most frequent malignancy in Caucasian populations. Evidence suggests the
involvement of cutaneous Human Papillomavirus (HPV) of the genus beta (β) in this disease. The ability of E6
and E7 of mucosal HPV to promote cellular transformation and inhibit immune response-related pathways
plays a key role in cervical carcinogenesis. β HPV-38 E6 and E7 display transforming activities in in vitro and
in vivo models, but their impact on immune surveillance is unknown. Here we show that HPV-38 E6 and E7
affect the IFN-induced up-regulation of MHC class I. Expression of the two viral proteins in HaCaT
keratinocytes led to a decrease of MHC I levels. This down-regulation is associated with a reduction of
expression of MHC I heavy chain, of the peptide chaperone TAP and of the STAT-1 downstream effector IRF-1.
The down-regulation of these proteins is ultimately due to the inhibition of STAT-1 expression. Analysis of
cells expressing either HPV-38 E6 or E7 suggests that these effects are primarily the result of E6 expression,
although a contribution by E7 cannot be excluded. We conclude that HPV-38 encodes oncoproteins that
potentially contribute to the evasion of host immune surveillance.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe E6 and E7 proteins of high risk mucosal αHPV (principally
HPV-16 and HPV-18) inhibit components of the biosynthetic pathway
of major histocompatibility class I (MHC I) such as class I heavy chain
(HC), TAP-1 (transporter associated with peptide) and LMP-2 (low
molecular weight protein) (Georgopoulos et al., 2000), and of the
interferon (IFN) network, such as ISGF-3, IRF-1, IRF-3, STAT-1 and TYK-
2 (Li et al., 1999; Nees et al., 2001; Park et al., 2000; Perea et al., 2000;
Ronco et al., 1998). It appears that the high risk viral oncoproteins can
affect these important immunological responses in a more severe way
than the corresponding low risk proteins (O'Brien and Campo, 2003),
in agreement with the numerous observations that high risk HPV E6
and E7 impact on the cell cycle regulatory machinery and tumour
suppressors more than their low risk HPV counterparts.
Non-melanoma skin cancer (NMSC) is the most frequent malig-
nancy in the Caucasian population and several lines of evidence
suggest the involvement of β genus cutaneous HPVs in the disease.
A subset of βHPVs was ﬁrst isolated from patients with Epi-
dermodysplasia Verruciformis (EV); in patients infectionwith EV-HPVnces, Institute of Comparative
asgow G61 1QH, Scotland, UK.
.
l rights reserved.types results in large numbers of warts, which progress to cancer in
30% of cases (IARC Monographs, 2005; Jablonska, 1991).
Highly sensitive polymerase chain reaction (PCR)-based assays for
HPV DNA detection have shown that the presence of βHPV DNA is not
exclusively restricted to skin lesions of EV patients, but can also be
frequently found in NMSCs of immuno-compromised and immuno-
competent individuals (Akgul et al., 2006; de Villiers et al., 1997;
Harwood et al., 2000). In addition, βHPV have been detected in
healthy skin (Asgari et al., 2008; Astori et al., 1998; Boxman et al.,
1997) and pre-cancer lesions (Harwood et al., 2000; Jong-Tieben et al.,
1995) suggesting a possible early role for HPV in the initiation of
NMSC.
Given the high multiplicity and wide distribution of βHPVs, and
their presence in normal skin, it is not clear if some types can be
unequivocally linked to cancer as in the case of αHPVs.
One of the best characterised βHPVs is HPV-38. HPV-38 has been
found in approximately 50% of NMSC (Caldeira et al., 2003), although
other authors ﬁnd this virus in a much lower percentage of case (see
Hazard et al., 2006). HPV-38 E6 and E7 proteins transform primary
human keratinocytes (Caldeira et al., 2003) and induce hyperproli-
feration and neoplasia in transgenicmice (Dong et al., 2005), similar in
these respects to HPV-16 E6 and E7. To further characterise HPV-38,
we analysed its impact on immune molecules, namely whether
expression of HPV-38 E6 and E7 proteins is prejudicial to the integrity
of MHC class I and the components of the IFN response, as is the case
409P. Cordano et al. / Virology 377 (2008) 408–418for the E6 and E7 proteins of high risk HPV-16 and HPV-18 (Ronco
et al., 1998; Barnard and McMillan, 1999; Li et al., 1999; Park et al.,
2000; Perea et al., 2000; Nees et al., 2001).
Results
Generation of HaCaT cell lines expressing HPV-38 oncoproteins
Stable HaCaT cell lines were obtained after infection with high-titre
recombinant retroviruses encoding E6 and/or E7 from HPV-38 (38E6E7,
38E6 or 38E7). HaCaT cells carrying empty retrovirus provided the
control. The HPV-38 and control cell lines were pools of infected G418-
resistant cells; pooling insured that maximum numbers of cells were
analysed and that theeffects observedwerenot due to the characteristics
of individual clones. Furthermore, the cells were kept frozen and thawed
when needed, thus preventing the out-growth of a dominant clone.
No antibodies are available to detect the HPV-38 proteins and
thereforewemonitored their expression by quantifying their respective
mRNAs by quantitative RT-PCR (Q-RT-PCR). E6 and E7 transcripts were
detected in approximately the same amounts in HaCaT 38E6 and HaCaT
38E7 cells respectively, whereas fewer 38E6 transcripts than 38E7
transcripts were consistently detected in HaCaT 38E6E7 cells (Fig. 1).
This may be due to splicing events in the bicistronic E6E7 mRNA as
shown forHPV-16 (Tang et al., 2006). This lower level of 38E6 transcripts
did not however result into loss of protein activity (see below).
Since E6 and E7 are expressed as bicistronic mRNA during natural
infection, we initially determined the effect of both HPV-38
oncoproteins on cellular proteins crucial to the immune response.
MHC class I is down-regulated in HaCaT cells expressing E6E7 proteins of
HPV-38
The expression of cell surface MHC class I (MHC I) was assessed by
ﬂow cytometry both in basal conditions and after treatment with either
type I interferon (IFNβ) or type II interferon (IFNγ) using mAb W6/32,
which recognises monomorphic determinants in human MHC I.
In 38E6E7 cells there was a consistent decrease in surface MHC I in
basal conditions. Although small, between 30% and 40% of the MHC I
level in control cells, this decrease was consistent and reproducible (p:
0.04; Figs. 2A, B). Levels of surface MHC I were also lower after
treatment with IFNβ or IFNγ: levels of surface MHC I were appro-
ximately 60% of those of control cells after IFNβ treatment in 38E6E7
cells (p: 0.017) and approximately 75–80% of those of control cells
after IFNγ treatment (p: 0.015) (Figs. 2A, B).
HPV-38 E6E7 proteins down-regulate the heavy chain component of MHC I
MHC I is a trimeric complex made up of heavy chain (HC), β2
microglobulin (β2 m) and peptide. To see if the decrease in surfaceFig. 1. HPV-38 E6 and E7 transcription in HaCaT cells. Quantitative RT-PCR (Q-RT-PCR)
for 38E6 or 38E7 in cells expressing either or both proteins. The mRNAs were measured
relative to 18S rRNA. The bars represent the adjusted error.
Fig. 2. Flow cytometry analysis of HaCaT cells expressing HPV-38 E6E7 proteins. Mean
forward ﬂuorescence of cell surface MHC class I in basal conditions and after exposure
to IFNβ or IFNγ (30 min). The graph shows the results from at least three experiments in
duplicate for control cells and 38E6E7 cells (A). The bars represent standard deviation
(SD). A representative ﬂow cytometry proﬁle for control and 38E6E7 cells is shown, the
numbers next to the peaks represent the mean forward ﬂuorescence of the respective
proﬁles (B).MHC I in 38E6E7 cells was due to a decrease in the expression of its
components, we assessed the levels of the β2m and HC proteins by
immunoblotting. We found that there were no differences in levels of
β2m between control and test cells (data not shown) but levels of HC
were lower in HaCaT 38E6E7 after IFN treatment (Figs. 3A and B, top
panels). We investigated the transcription of the HC gene by Q-RT-PCR
Fig. 3.HPV-38 E6E7 down-regulate immunemolecules. (A) Western blot analysis of HaCaT cells expressing HPV-38 E6E7 proteins. Protein lysates from control or 38E6E7 cells grown
in basal conditions or in the presence of IFNβ or IFNγ were immunoblotted for: MHC I heavy chain with anti-HC10 mouse monoclonal antibody (CRT, UK); TAP-1 with anti-TAP-1
(753-748) rabbit polyclonal antibody (Merck Biosciences, UK); IRF-1 with anti-IRF-1 mouse monoclonal antibody (BD Biosciences, UK); STAT-1 with anti-STAT-1 (C-terminus) mouse
monoclonal antibody (BD Biosciences, UK), and phosphorylated STAT-1 (pSTAT-1) with anti-phospho-STAT-1 (Tyr 701) rabbit polyclonal antibody (New England Biolabs, UK). Actin
was detected with anti-actin mouse monoclonal antibody Ab-1 (Oncogene™, UK) as loading control. The MHC I heavy chain (HC) blot was under-exposed to better show the
differences in HC after IFN treatment. IFN treatment was 48 h for MHC I heavy chain, TAP-1 and IRF-1, and 30 min for STAT-1 and pSTAT-1. (B) Densitometric analysis of at least three
blots similar to the ones in A. The density (volume) of the bands in control cells in basal conditionwas adjusted for the density of the corresponding actin bands and taken as 100. The
bands from the test cells were referred to the control band. The measurements were repeated at least three times with similar results. The bars represent SD.
410 P. Cordano et al. / Virology 377 (2008) 408–418and found that, despite the reduction in HC protein, there were no
differences in HC RNA between control cells and 38E6E7 cells either in
basal conditions or after IFN treatment (Supplementary information,
Fig. 1).HPV-38 E6E7 proteins down-regulate TAP expression
The assembly of theMHC I complex needs amultitude of chaperons,
such as tapasin and TAP-1 (transporter associated with peptide)
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the assembly of MHC I is prevented, free HC is degraded (Hughes et al.,
1997). Given the results above, which suggest that the reduction inHC is
post-transcriptional, we examined the expression of TAP-1 by immuno-
blotting in cells expressing 38E6E7. TAP-1 was reduced in 38E6E7 cells
after IFN treatment, particularly IFNγ (Figs. 3A and B, second panels).
To ascertain if, as in the case of MHC I HC, the reduction in TAP-1
level was post-transcriptional, we performed Q-RT-PCR for TAP-1
transcripts in basal condition and after IFN treatment. We found lower
levels of TAP-1 transcripts in 38E6E7 cells than in control cells (Fig. 4A).Fig. 4. HPV-38 E6E7 down-regulate transcription of mRNA encoding immune proteins. Quan
38E6E7 cells grown in basal conditions or treated with IFN. ThemRNAs weremeasured relati
of STAT-1mRNA after IFNβ or IFNγ has been done at different times. (D), HPV-38 E6 down-re
assays with TAP-1, LMP-2 and IRF-1 promoters in control and 38E6E7 cells in basal conditio
control cells. The bars represent SD.It therefore appears that the expression of 38E6E7 affects transcription
of the TAP-1 gene.
HPV-38 E6E7 proteins impact on the IFN network
One upstream regulator of the TAP gene promoter is the interferon
responsive factor 1 (IRF-1) (White et al., 1996) and it has been shown that
HPV-16 E7 binds to and inhibits IRF-1 (Perea et al., 2000). We therefore
examined the expression of IRF-1 in 38E6E7 cells. IRF-1 was down-
regulated in 38E6E7 cells after IFNβ treatmentwhile treatmentwith IFNγtitative RT-PCR (Q-RT-PCR) for TAP-1 (A), IRF-1 (B) and STAT-1 (C) mRNA in control and
ve to 18S rRNA. The bars represent the adjusted error. Please note that the determination
gulates the transcriptional promoters of TAP-1, LMP-2 and IRF-1. Luciferase transcription
n and after IFN treatment. Promoter activity is expressed as fold increase over that of
Fig. 5. HPV-38 E6E7 down-regulate STAT-1 but do not inhibit its translocation to the
nucleus. A, Western blot of cytoplasmic and nuclear STAT-1 and pSTAT-1 probed with
anti-STAT-1 (C-terminus) mouse monoclonal antibody (BD Biosciences, UK) and anti-
pSTAT-1 (Tyr 701) rabbit polyclonal antibody (New England Biolabs, UK). GAPDH and
Lamin were chosen as cytoplasmic and nuclear markers respectively. B, Quantitation of
nuclear/cytoplasmic ratio of pSTAT-1 after IFN treatment. Quantitation in basal
conditions is not possible as pSTAT-1 is translocated to the nucleus in detectable
amounts only after IFN treatment. Quantitation was done as in Fig. 3.
Fig. 6. HPV-38 E6E7 down-regulate STAT-1 in immortalised primary human
keratinocytes. (A), Control primary human keratinocytes, HPV-38i and HPV-38.1
keratinocytes (Caldeira et al., 2003; Gabet et al., 2008) were grown either in basal
conditions or in the presence of IFNβ for 30 min, and protein lysates were
immunoblotted with anti-STAT-1 (C-terminus) mouse monoclonal antibody (BD
Biosciences, UK) and anti-pSTAT-1 (Tyr 701) rabbit polyclonal antibody (New England
Biolabs, UK). Actin was detected with anti-actin mouse monoclonal antibody Ab-1
(Oncogene™, UK) as loading control. (B) Densitometric analysis of at least three blots for
STAT-1, and one blot for pSTAT-1. The density of the STAT-1 bands was calculated as in
Fig. 3. The measurements were repeated several times with similar results.
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agreement with the fact that IFNγ is the strongest IRF-1 inducer known
(Kroger et al., 2002).
As for TAP-1, we looked at the levels of IRF-1 transcripts by Q-RT-
PCR and IRF-1 RNA was lower in 38E6E7 cells than in control cells in
basal conditions and after IFN treatment, particularly IFNβ (Fig. 4B).
The apparent discrepancy between the immunoblotting and the Q-
RT-PCR results (cf Figs. 3A,B with Figs. 4A,B) can be explained by the
different sensitivities of the two techniques. Q-RT-PCR is exquisitely
sensitive to differences in RNA levels, whereas immunoblotting detects
larger differences in protein levels.
HPV-38 E6E7 proteins affect the transcriptional activities of the TAP-1,
LMP-2 and IRF-1 promoters
Wenext investigated how38E6E7 affect the RNA levels of TAP-1 and
IRF-1 by the use of their respective transcriptional promoters. The TAP
promoter is a bi-directional one controlling the transcription of bothTAP
and the proteasome subunit LMP-2 (Wright et al., 1995). The promoters
for TAP-1, LMP-2 and IRF-1, cloned upstream of the luciferase reporter
gene,were introduced into control and38E6E7cells. All threepromoters
were greatly inhibited in the 38E6E7 cells (Fig. 4D), indicating that the
reduction in the respective RNA and proteinswas due to an inhibition of
their promoters by the viral proteins. The TAP-1 and IRF-1 promoters
were assayed also after IFN treatment and also in this case they showed
decrease activity in 38E6E7 cells (Fig. 4D).
HPV-38 E6E7 proteins affect the levels of STAT-1
38E6E7 appear to impact on both IFNβ and IFNγ pathways.
Although type I and type II IFNs trigger two parallel signal cascades,their pathways intersect at several points and one component
common to both pathways is STAT-1 (Goodbourn et al., 2000). Upon
activation by IFN, STAT-1 either heterodimerises with STAT-2 (IFNβ),
or homodimerises with another molecule of STAT-1 (IFNγ). The
dimers are phosphorylated and translocated to the nucleus where
they engage their respective targets. One of the targets of STAT-1 is
IRF-1 (Ohmori et al., 1997). Given the pivotal role of STAT-1 in the IFN
networks, and the reduction of IRF-1 in 38E6E7 cells, we investigated
if STAT-1 or its activity would be inhibited by HPV-38 proteins. We
found that the levels of STAT-1 in the 38E6E7 cells were lower than
those in control cells both in basal conditions and in IFN stimulated
cells; there was accordingly less phosphorylated STAT-1 (pSTAT-1)
overall, but the residual STAT-1 appeared to be slightly more
phosphorylated than in control cells (Figs. 3A and B, bottom panels).
As pSTAT-1 is translocated to the nucleus, we analysed its transloca-
tion in control and 38E6E7 cells but found no difference between the
two cell lines (Fig. 5). As there were no changes between control and
38E6E7 cells in either TYK-2, the proximal effectors of the IFN
Fig. 7. STAT-1 is not degraded by HPV-38 E6E7. (A) Control cells or 38E6E7 cells were treated with MG132 and protein lysates were immunoblotted for STAT-1 with anti-STAT-1 (C-
terminus) mouse monoclonal antibody (BD Biosciences, UK). (B) Densitometric analysis of at least three blots similar to the one in A. The density of the STAT-1 bands was adjusted for
the density of the actin bands. The bars represent SD. (C) Control cells or 38E6E7 cells were treated with cycloexamide (CHX) for varying hours (1, 2, 5, 10 and 24) and protein lysates
were immunoblotted for STAT-1 with anti-STAT-1 (C-terminus) mouse monoclonal antibody (BD Biosciences, UK). Actin was detected with anti-actin mouse monoclonal antibody
Ab-1 (Oncogene™, UK) as loading control in A and B. (D) Densitometric analysis of the blots in C. The density of the STAT-1 bands was calculated as in Fig. 3.
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that 38E6E7 target STAT-1.
HPV-38 E6E7 proteins inhibit STAT-1 in immortalised primary human
keratinocytes
HaCaTcells have been extensively and fruitfully used in the study of
HPV. However, the possibility existed, albeit remote, that the observed
effects were due, at least partly, to the nature of the HaCaT cells.
Therefore we investigated the levels of STAT-1 in two independently
derived lines of primary human keratinocytes which had been
immortalised and transformed by HPV-38 E6E7 (Caldeira et al.,
2003; Gabet et al., 2008). Also in these cells, 38E6E7 caused a marked
decrease of STAT-1 and a corresponding decrease of pSTAT-1 both in
basal conditions and after IFNβ treatment (Fig. 6). The results obtained
with IFNγ were inconsistent and require further investigation.
HPV-38 E6E7 proteins reduce the levels of STAT-1 mRNA
HPV-38 E6 does not degrade p53 (Caldeira et al., 2004); however the
possibility that the lower levels of STAT-1 in 38E6E7 cells were due to E6-
induced degradation could not be discounted. Thus, control and 38E6E7
cells were treated with either the proteasome inhibitor MG132, to see
whether STAT-1 was degraded, or with the protein synthesis inhibitor
cyclohexamide (CHX) to investigate STAT-1 half life. Neither inhibitor
had a major effect on STAT-1 in 38E6E7 cells compared to control cells,although it was clear in both experiments that the levels of STAT-1 were
lower in38E6E7 than incontrol cells. Therewasnosigniﬁcantdifference in
STAT-1 after MG132 treatment in either control or 38E6E7 cells (Figs. 7A
and B); STAT-1 had a similar half life in both control and 38E6E7 cells
(Fig. 7C and D), although small differences in decay kinetics cannot be
ruledout.Weconclude that thedecrease in STAT-1 levels in38E6E7cells is
unlikely to be due to degradation or higher turnover of STAT-1. Therefore,
to see if lower levels of STAT-1 in cells expressing38E6E7mightbedue to a
decrease in STAT-1 mRNA, we performed Q-RT-PCR for STAT-1 mRNA in
control and 38E6E7 cells. The amount of STAT-1 mRNA was decreased
in the test cells compared to control cells after IFN treatment (Fig. 4C),
indicating that 38E6E7 decrease levels of STAT-1 primarily by inhibiting
STAT-1 gene transcription.
The effects on IFN pathway are due to HPV-38 E6
To try to ascertainwhether HPV-38 E6 or E7 had the greater impact
on the IFN pathway, we analysed STAT-1, IRF-1, TAP-1 and MHC I in
cells expressing either E6 or E7. STAT-1, TAP-1, MHC I HC and surface
MHC I were all down-regulated in 38E6 cells (Figs. 8A and B).
However, the levels of IRF-1 did not seem to change between the two
cell lines (Fig. 8A, second panel). It could be argued that the lack of
discernible effect in the 38E7 cells was due to lack of E7 expression,
notwithstanding the presence of equivalent amounts of E6 and E7
mRNA in the two cell lines (Fig. 1). 38E7 degrades pRb (Caldeira et al.,
2003); therefore the status of pRb is a read out for E7 expression. pRb
414 P. Cordano et al. / Virology 377 (2008) 408–418was clearly reduced in 38E7 and 38E6E7 cells, but not in 38E6 cells as
expected (Supplementary information, Fig. 3), showing that E7 is
indeed expressed in those cell lines. Thus it appears that 38E6 has the
greater impact on the immune molecules analysed, but a contribution
by 38E7, particularly in the down-regulation of IRF-1 in 38E6E7 cells,
cannot be ruled out.Fig. 8. HPV-38 E6 down-regulates immune molecules. A, Western blot analysis of STAT-1, pST
were grown and lysed as described in Fig. 3. The protein lysates were run on gel and probed a
MHC I in HaCaT cells expressing either 38E6 or 38E7. Mean forward ﬂuorescence of cell surf
graph shows the results from at least three experiments in duplicate for control cells, 38E6 or
were reproducible, they were not statistically signiﬁcant because of variations in forward ﬂDiscussion
Viruses need to escape the host immune response to establish a
productive infection. HPV-16 E5 down-regulates surface MHC class I
(Ashraﬁ et al., 2005), thus potentially contributing to the evasion of the
host immune response by the viral infected cell. Although all E5 proteinsAT-1, IRF-1, TAP-1 and MHC I HC in HaCaT cells expressing either 38E6 or 38E7. The cells
s described in Fig. 3. The blots were quantiﬁed as in Fig. 3. B, Flow cytometry analysis of
ace MHC class I in basal conditions and after exposure to IFNβ or IFNγ, as in Fig. 2. The
38E7 cells. Although the differences in MHC I levels between 38E6 cells and control cells
uorescence between experiments.
Fig. 8 (continued ).
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do not have an E5 ORF and it is reasonable to assume that other viral
proteins would achieve a similar effect but using different mechanisms.
One of the downstream effects of both IFNβ and IFNγ is an increase
in expression of MHC I. HPV-16 and -18 E6 and E7 both interfere with
components of the IFN pathway (Li et al., 1999; Nees et al., 2001; Park
et al., 2000; Perea et al., 2000; Ronco et al., 1998), thus potentially
reducing the amount of MHC I on the cell surface.
Given the precedents for interference with the IFN pathways by
mucosal HPV E6 and E7, we investigated whether βHPV-38 E6 and E7
can likewise affect the interferon signalling cascade and one of its ﬁnal
steps, MHC I expression.
Indeed, we found that 38E6E7 inhibit STAT-1 and several of its
downstream signal transduction steps, including IRF-1, TAP-1 and
ultimately MHC I.
HPV-38 E6E7 proteins down-regulate STAT-1
Upon IFN treatment, STAT-1 either heterodimerises with STAT-2
(IFNβ), or homodimerises (IFNγ) and becomes phosphorylated. The
phosphorylated complexes are translocated to the nucleus where they
target their respectivepromoters.Oneof the targets of STAT-1 is the IRF-1
promoter. The IRF-1 promoter is inhibited in cells expressing38E6E7 and
this inhibition is not due to the failure to activate (phosphorylate) STAT-1
or to translocate activated pSTAT-1 to the nucleus, but to a decrease in
STAT-1 levels and therefore pSTAT-1 (Fig. 3 bottom panels and Fig. 5).
HPV-16 E6 binds to and promotes the degradation of numerous cellular
proteins (Mantovani andBanks, 2001). Thedown-regulation of STAT-1 in
38E6E7 cells, however, does not appear to be due to degradation or to
modiﬁcation of its half life (Fig. 7). Rather, the decrease in STAT-1 levels is
a consequence of a decrease in STAT-1 mRNA (Fig. 4). Although we have
not analysed speciﬁcally the activity of the transcriptional promoter of
the STAT-1 gene, we believe the reduction in STAT-1 transcripts is due to
an inhibition of the promoter, as found for the promoters of IRF-1, TAP-1
and LMP-2 (see below). How 38E6E7 affects transcription of the STAT-1gene is not yet known and this point deserves investigation. Preliminary
results suggest that down-regulation of STAT-1 is not due to gene
hypermethylation (Friedrichet al., 2005), or toup-regulation of the STAT-
1 negative controller STRA-13 (Ivanov et al., 2006).
It has to be pointed out that down-regulation of STAT-1 takes place
also in primary human keratinocytes immortalised by HPV-38 E6E7
(Fig. 6), ruling out an artefact due to the established nature of HaCaT
cells. STAT-1 is down-regulated in keratinocytes expressing 38E6E7
also after IFNβ treatment. No conclusions could bemade for IFNγ as its
effect was erratic and unreliable.
HPV-38 E6E7 proteins down-regulate IRF-1 and TAP-1
STAT-1 binds to and activates the transcription of the IRF-1 gene
(Ronco et al., 1998). IRF-1 transcriptional promoter is down-regulated
in 38E6E7 cells with low amounts of IRF-1 transcripts (Figs. 4B, D).
This is in agreement with the inhibition of STAT-1 by 38E6E7 (Fig. 3).
IRF-1 positively regulates the transcriptional promoter of the TAP-1
gene (Chatterjee-Kishore et al., 1998). Consistent with the down-
regulation of IRF-1, the TAP-1 promoter is also inhibited in 38E6E7 cells
(Figs. 4A and D). The transcriptional inhibition of TAP by 38E6E7 is in
agreement with previous results showing that oncogenic viruses such
as HPV-16 and adenovirus 12 inhibit TAP transcription (Georgopoulos
et al., 2000; Profﬁtt and Blair, 1997).
HPV-38 E6E7 proteins down-regulate MHC I
TAP-1 chaperones peptides to theMHC I complex, and the complex
needs peptide to be stable. A decrease in TAP leads to unstable MHC I
and degradation of HC. Indeed loss of TAP-1 is highly correlated with
loss of MHC I in cervical carcinomas (Cromme et al., 1994).
38E6E7 cells have consistent lower levels of surface MHC I than
control cells, down by approximately 20–40% (Fig. 2). Although small,
and less than the one found in HaCaT cells expressing HPV-16 E5
(Ashraﬁ et al., 2005), this decrease is comparable to the one reported
in cells expressing the pre-S2 antigen of woodchuck hepatitis B virus
or the full genome of HBV (Chen et al., 2006; Wang and Michalak,
2006). It remains to be seen if this extent of MHC I down-regulation
leads to escape from CTL recognition. These experiments cannot be
performed in HaCaT cells as they express primarily HLA-A3 and to our
knowledge no HLA-A3-restricted CTL lines exist.
The changes in immunemolecules observed in 38E6E7 cells appear
to be due primarily to 38E6, althoughwe cannot rule out amore subtle
contribution by 38E7 particularly to the down-regulation of IRF-1.
It has been reported that HPV-16 E7 interfereswith IRF-1, because of
a direct binding between 16E7 and IRF-1 (Park et al., 2000; Perea et al.,
2000), andwith TAP-1, partly because of the inhibition of the TAP-1 gene
promoter (Georgopoulos et al., 2000). In contrast to what found with
HPV-16, HPV-38 E6 appears to have a greater impact on TAP-1 down-
regulation than 38E7 (cf Fig. 3 with Fig. 8), and may co-operate with
38E7 in IRF-1 down-regulation, as IRF-1 levels are lower in 38E6E7 cells
than in either 38E6 or 38E7 cells (cf Fig. 3 with Fig. 8).
The targeting of STAT-1 by 38E6E7 and particularly by 38E6 is in
agreement with the previous observation that STAT-1 is strongly down-
regulated by high riskmucosal HPV (Barnard andMcMillan,1999; Chang
and Laimins, 2000; Li et al., 1999; Nees et al., 2001), although the
mechanisms appear to be different. For instance HPV-18 E6 associates
with TYK-2 – the upstream regulator of STAT-1 – and impairs the
activation of the JAK-STAT cascade (Li et al., 1999). In contrast, in HPV-38
cells, TYK-2 is not affected, and the down-regulation of STAT-1 is atmRNA
level. STAT-1 is part of both IFN type I and IFN type II pathway so
its inhibition would affect both pathways, without need for 38E6E7 to
down-regulate STAT-2, as is indeed the case (Supplementary information,
Fig. 2).
Mostof thecell transformingactivityofβHPVs appears tobeencoded
by their E6 genes (Massimi et al., 2008). In agreement, thepresent results
416 P. Cordano et al. / Virology 377 (2008) 408–418concur with this observation suggesting that the E6 proteins of βHPVs
may be more potent in their action than the corresponding E7.
Materials and methods
Cells and transfection
pLXSN38E6E7 has been previously described (Caldeira et al., 2003).
TheHPV-38 E6 and E7 geneswere each ampliﬁed from the viral genome
by PCR and subcloned into the retroviral pLXSN vector (Clontech, USA)
between EcoRI and XhoI sites to generate pLXSN38E6 or pLXSN38E7
vectors. The constructs were then transfected into Phoenix cells (Pear
et al., 1993) using CalPhos™ Mammalian Transfection Kit (Clontech,
USA), and high-titre retroviral supernatants were obtained by culturing
the cells for an extra 24 h. Supernatants were passed twice through
0.45 μm ﬁlters to remove all virus-producing cells and used to infect
HaCaT cells.
HaCaTcells were grown in 25 cm3 ﬂask in Dulbecco'smodiﬁed Eagle
mediumHigh Glucosewithout calcium chloride (Life Technologies, UK),
supplemented with 10% foetal calf serum, 4 mM L-glutamine, 100 IU
penicillin per ml, and 100 μg streptomycin per ml until approximately
70% conﬂuent (1x106). HaCaT cells were infected with high-titre
retroviral supernatants (pLXSN38E6E7, pLXSN38E6 or pLXSN38E7)
and 24 h after infection were washed, trypsinised, placed in 75 cm3
ﬂasks and selected in growth medium containing 800 μg/ml G418.
Selection continued until all the non-infected control cells had died
(approximately two weeks). Due to the high-titre virus we did not
observe signiﬁcant levels of death in infected HaCaT cells. The infected
cells were then pooled and frozen, and maintained in growth medium
containing 400 μg/ml G418 when needed.
Primary human foreskin keratinocytes were transduced with empty
retrovirus pLXSN (control), or with pLXSN38E6E7 (38E6E7i) as de-
scribed by Caldeira et al., 2003. The keratinocytes line 38E6E7.1 is
derived from human embryonic keratinocytes (Cascade, USA) as de-
scribed by Gabet et al., 2008.
Interferon treatment
Cells were left to set for 24 h after seeding and then treated with
either IFNβ (500U/ml) (R&D Systems, UK) or IFNγ (0.075 μg/ml)
(Sigma-Aldrich, UK) for 30 min for the study of STAT-1. This timing
was decided based upon published observations (Haspel et al., 1996)
and our own (data not shown) that the appearance of phosphorylated
STAT-1 (pSTAT-1) in the nucleus was maximal within 20–30 min after
treatment.
For the study ofMHC I, the treatment has to be longer to allow time
for maturation of the complex, and it was established that optimal
treatment time was 48 h (data not shown). The analysis of IRF-1 and
TAP-1 was also done after 48 h IFN treatment.
Detection of MHC class I by ﬂow cytometry
HaCaT cells expressing E6 and/or E7 of HPV-38 and control cells
were incubated with anti-human HLA class I mouse monoclonal
antibodyW6/32 (1/100) (Serotec, UK) at 4 °C for 30min, and thenwith
anti-mouse IgG-FITC (1/100) (Sigma-Aldrich, UK) at 4 °C for 30 min in
the dark. After washing, the cells were re-suspended in 500 ml of 3.4%
paraformaldehyde in PBS and kept at 4 °C. Samples were examined in
a Beckman Coulter EPICS Elite analyser equipped with an ion argon
laser with 15 mV of excitation at 488 nm. The data were analysed
using Expo 2 software.
Antibodies for Western blot
The following primary antibodies were used: anti-STAT-1 (C-
terminus) mouse monoclonal antibody (BD Biosciences, UK); anti-phospho-STAT-1 (Tyr 701) rabbit polyclonal antibody (New England
Biolabs, UK); anti-TAP-1 (753-748) rabbit polyclonal antibody (Merck
Biosciences, UK); anti-IRF-1 mouse monoclonal antibody (BD Bios-
ciences, UK); anti-STAT-2 mouse monoclonal antibody (BD Biosciences,
UK); anti-Tyk2 mouse monoclonal antibody (BD Biosciences, UK);
anti-tapasin rabbit polyclonal antibody (Abcam, UK); anti β2 micro-
globulin (BBM.1) mouse monoclonal antibody (Cancer Research UK
Technologies [CRT], UK); anti-MHC I heavy chain (HC10) mouse
monoclonal antibody (CRT); anti-lamin B1 rabbit polyclonal (Abcam,
UK); mouse monoclonal anti-GAPDH (Abcam, UK); anti-actin mouse
monoclonal antibody Ab-1 (Oncogene™, UK), anti-pRb (clone G3-245)
mouse monoclonal antibody (Pharmingen, UK). The secondary
antibodies used were either GPR, a sheep anti-mouse Ig, linked to
horseradish peroxidase (GE Healthcare, UK) or goat anti-rabbit IgG
(whole molecule)-peroxidase antibody (Sigma-Aldrich, UK).
Western blot analysis
HaCaTcells expressing HPV-38 oncoproteins and control cells were
treated with IFN for either 30 min or for 48 h. Cells were lysed in SDS-
lysis buffer (100mM Tris–HCl, pH 6.8, 2% SDS, 2% glycerol), clariﬁed by
centrifugation for 10 min at 4 °C and the supernatant was recovered.
Protein concentration was determined by absorbance measurement
at 562 nm. 10 μg of each sample were electrophoresed on Nu PAGE™
4–12% Bis–Tris gel (Invitrogen, UK) under denaturing conditions and
transferred onto a nitrocellulose membrane (Invitrogen, UK). Mem-
branes were incubated with varying primary antibodies (for STAT-1,
pSTAT-1, STAT-2, Tyk2, TAP-1, IRF-1, β2m, MHC I heavy chain, tapasin)
followed by incubation with the corresponding secondary antibodies
HRP-conjugated. Western blots were developed by enhanced chemi-
luminescence (ECL Plus, GE Healthcare, UK).
To study possible degradation of STAT-1, 38E6E7 cells and control
cells were treated for 8 h with 5 μM MG132 (Calbiochem, UK) before
further processing, whereas to investigate STAT-1 half life the cells
were treated with 0.1 mg/ml of the protein synthesis inhibitor
cyclohexamide (CXH) (Sigma-Aldrich, UK) for several hours (1, 2, 5, 10,
24 h).
Bands were analysed by densitometry using a STORM860 scanner
(molecular Dynamics, UK) and ImageQuant TL version 2005 software
(Amersham Biosciences, UK). In all cases, the density of the bands was
adjusted to the density of the corresponding actin bands, and the
bands of control cells in basal conditions were arbitrarily taken as 100.
All the other bands were referred to the control bands.
Nuclear-cytoplasm fractionation
Cells were grown and treated as explained forWestern blot and the
nuclear and cytoplasmic fractions were separated using a Nuclear
Extraction Kit (Imgemex, Cambridge Bioscience, UK) following the
instructions of the supplier. One μg only of each sample (to avoid
precipitation with loading buffer) was electrophoresed as indicated
for Western Blot. To control the efﬁciency of fractionation the blots
were stained with either rabbit polyclonal antiserum to Lamin B1
(Abcam, UK) for the nuclear fraction, or GAPDH (Abcam, UK) for the
cytoplasmic fraction.
Quantitative RT-PCR
Quantitative RT-PCR was employed to monitor the expression of
HPV-38 oncoproteins, the heavy chain of MHC class I, TAP-1, IRF-1 and
STAT-1. Cells were seeded and treated as described for Western blot,
and total RNAwas extracted using RNeasy®Mini Kit (QIAGEN, UK) and
treated with DNase I, Ampliﬁcation Grade kit (Invitrogen, UK) prior to
RT-PCR. The reverse transcription was primed with Random Primers
(Promega, UK) at a concentration of 0.2 μg in a 12 μl reaction mixture
that was then reverse-transcribed using theMMoLV RT kit (Invitrogen,
417P. Cordano et al. / Virology 377 (2008) 408–418UK) in a volume of 20 μl containing 1× First-Strand Buffer, 11 mM DTT,
40 U RNaseOUT™ Recombinant Ribonuclease Inhibitor and 200U
MMoLV RT following the instructions of the supplier.
cDNA was ampliﬁed in triplicate either for HPV-38 E6 with the
primers 5′ tttttgcatgttgtagcagttgtg and 5′cacggccaaagacagttaattca or
for HPV-38 E7 with the primers 5′ tgcattgccacgaggagtt and 5′
tggctcctcctctaccactga, at a concentration of 600 mM each in a 25 μl
reaction that contained 12.5 μl TaqMan®Universal PCRMasterMix, No
Amperase® UNG (Applied Biosystems, UK). The reactions also
contained the detection TaqMan® probes: 6FAM -5′ ttatgcttctgctcaa-
tatgaatgtcagcagtttt – TAMRA for HPV-38 E6 and 6FAM -5′ cctgatcttc-
cagaggatattgaagc – TAMRA for HPV-38 E7 respectively, both at a
concentration of 4 μM.
cDNA was ampliﬁed in triplicate for STAT-1 with the primers 5′
ccagcctggtttggtaattga and 5′ gctggctgacgttggagatc at a concentration of
600 mM each in a 25 μl reaction that contained 12.5 μl TaqMan®Uni-
versal PCR Master Mix, No Amperase® UNG (Applied Biosystems, UK).
The reaction also contained thedetectionprobeTaqMan®Probe: 6FAM-
agacgacctctctgcccgttgtgg – TAMRA, at a concentration of 4 μM.
cDNA were ampliﬁed in triplicate for TAP-1 and IRF-1 using the
corresponding Pre-Developed TaqMan® Gene Expression Assays
(Applied Biosystems, UK).
As control cDNA were ampliﬁed with the Pre-Developed Assay
Reagents for Eukaryotic 18S rRNA Endogenous Control (FAM™ Dye /
MGB Probe, Non-Primer Limited) (Applied Biosystems, UK).
The thermal cycling conditions were 2 min at 50 °C and 10 min at
95 °C, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All
reactions were performed in the model 7500 Sequence Detector
(Applied Biosystems, UK).
The results were plotted in a graph as percentage of 2−ΔΔCt ac-
cording to published methods (Livak and Schmittgen, 2001).
Luciferase reporter assays
Cells were seeded in 60 mm plates and were transfected with 1 μg
of the luciferase reporter plasmids pIRF-1, pTAP-1 or pLMP2 (kind gifts
of Y. Ohmori and E. Blair respectively), using LIPOFECTAMINE PLUS™
Reagent (Life Technologies, UK) according to the manufacturer's in-
structions. Forty-eight hours post-transfection the cells were har-
vested and the luciferase assays were performed according to the
instructions of the supplier (Promega, UK).
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